Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Immunoclin Corp | exhibit311.htm |
| EX-32.1 - EXHIBIT 32.1 - Immunoclin Corp | exhibit321.htm |
| EX-31.2 - EXHIBIT 31.2 - Immunoclin Corp | exhibit312.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Immunoclin Corp | Financial_Report.xls |
| 10-Q - FORM 10-Q - Immunoclin Corp | form10q.htm |
| Exhibit 32.2 |
|
|
| Certification Pursuant to18 U.S.C. Section 1350 as Adopted Pursuant to |
| Section 906 of the Sarbanes-Oxley Act of 2002 |
In connection with the Quarterly Report of Pharma Investing News, Inc., (the “Company”) on Form 10-Q for the period ended May 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Chad Johnson, Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
| 1 | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
| 2 | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
By: /s/ Chad Johnson
Chad Johnson
Chief Financial Officer
July 22, 2013
|
|